Literature DB >> 11441120

CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion.

A Hombach1, C Heuser, T Marquardt, A Wieczarkowiecz, V Groneck, C Pohl, H Abken.   

Abstract

T cells engrafted by a recombinant immunoreceptor with predefined Ag specificity can efficiently lyse Ag-positive target cells in a MHC Ag-independent manner. It is yet unresolved how receptor-grafted CD4+ T cells contribute to MHC Ag-independent target cell lysis. To address this issue, we grafted isolated CD8+ and CD4+ T cells from the peripheral blood with recombinant anti-carcinoembryonic Ag and anti-CD30 receptors, respectively. Cytotoxicity analyses revealed that grafted CD4+ T cells exert cytolysis of Ag-positive target cells with an efficiency similar to that of grafted CD8+ T cells. Lysis by receptor-grafted CD4+ T cells is Ag specific and is inhibited by blocking the target Ag or the Ag binding site of the recombinant receptor. Both Fas-sensitive and Fas-resistant target cells are lysed with equal efficiency, and lysis of Fas-sensitive target cells is not blocked by an anti-Fas ligand Ab, indicating that cytolysis by receptor-grafted CD4+ T cells is independent of the Fas pathway. We conclude that cytolysis by CD4+ T cells equipped with a recombinant immunoreceptor is MHC Ag and Fas independent and likely to be mediated by perforin present in receptor-grafted CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441120     DOI: 10.4049/jimmunol.167.2.1090

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.

Authors:  Amitesh Verma; Sarwish Rafiq
Journal:  Cancer Treat Res       Date:  2022

Review 2.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 3.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

4.  Acute cardiac allograft rejection by directly cytotoxic CD4 T cells: parallel requirements for Fas and perforin.

Authors:  Todd J Grazia; Robert J Plenter; Sarah M Weber; Helen M Lepper; Francisco Victorino; Martin R Zamora; Biagio A Pietra; Ronald G Gill
Journal:  Transplantation       Date:  2010-01-15       Impact factor: 4.939

5.  HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.

Authors:  Jun Lin; Chang-Sheng Deng; Jie Sun; Xian-Gong Zheng; Xing Huang; Yan Zhou; Ping Xiong; Ya-Ping Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 6.  Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Authors:  Marcela V Maus; Bruce L Levine
Journal:  Oncologist       Date:  2016-03-23

Review 7.  Focus on adoptive T cell transfer trials in melanoma.

Authors:  Liat Hershkovitz; Jacob Schachter; Avraham J Treves; Michal J Besser
Journal:  Clin Dev Immunol       Date:  2010-12-26

Review 8.  Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review.

Authors:  Sandeep Nayar; Prokar Dasgupta; Christine Galustian
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 9.  Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells.

Authors:  Markus Chmielewski; Andreas A Hombach; Hinrich Abken
Journal:  Front Immunol       Date:  2013-11-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.